Vivian Rexroad, PharmD

CRS:

JHU

Role:

Pharmacy

Position:

Pharmacist, PharmD, Investigational Drug Pharmacy

Email:

vrexroa@jhmi.edu
  • Network Pharmacist, IMPAACT Leadership
  • Member, IMPAACT Multidisciplinary Protocol Review Group
  • Protocol team member for IMPAACT 1078, IMPAACT 1114 and IMPAACT 2000
  • General Member (Pharmacist), Protocol Development and Implementation Subcommittee of the SMCCC (Feb 2016-Nov2017
  • Member, Pharmacy Working Group of the PDISC (Feb 2016)
  • Member, Site Pharmacist Working Group of the Pharmacy Subcommittee

Categories

Leadership Committees
CRS
Roles

Clinical Trials

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More

A5346: Sitagliptin for Reducing Inflammation and Immune...

The purpose of the study is to evaluate whether sitagliptin (Januvia is the brand name for sitagliptin)...

Read More

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled...

P1078 is a Phase IV, randomized, double-blind, placebo-controlled study of HIV-infected pregnant women and the infants born to...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More